E-cadherin polymorphisms and haplotypes influence risk for prostate cancer

Prostate

Volumn 66, Issue 5, 2006, Pages 546-556

  Bonilla, Carolina ^a,b   Mason, Tshela ^b   Long, Layron ^b   Ahaghotu, Chiledum ^b,c   Chen, Weidong ^b   Zhao, Aiqiu ^b   Coulibaly, Aoua ^b   Bennett, Frankly ^d   Aiken, William ^d   Tullock, Trevor ^d   Coard, Kathleen ^d   Freeman, Vincent ^e,f   Kittles, Rick A ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c HOWARD UNIVERSITY HOSPITAL   (United States)

^d UNIVERSITY OF THE WEST INDIES   (Jamaica)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

African Americans; CDH1; Haplotypes; Prostate cancer; Single nucleotide polymorphisms (SNP); Tumor suppressor

Indexed keywords

UVOMORULIN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER RISK; CDH1 GENE; CONTROLLED STUDY; ETHNIC GROUP; EUROPEAN AMERICAN; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; JAMAICA; JAMAICAN; MAJOR CLINICAL STUDY; MALE; PENETRANCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

AFRICAN AMERICANS; AGED; CADHERINS; EXONS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRONS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SEQUENCE DELETION; UNITED STATES;

EID: 33645377502     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20374     Document Type: Article

References (44)

1. Siddiqui E, Mumtaz F, Gellster J. Understanding prostate cancer. J R Soc Health 2004;124(5):219-221.
2. Simard J, Dumont M, Labuda D, Sinnett D, Meloche C, El-Alfy M, Berger L, Lees E, Labrie F, Tavtigian S. Prostate cancer susceptibility genes: Lessons learned and challenges posed. Endocr Relat Cancer 2003;10(2):225-259.
3. Gsur A, Feik E, Madersbacher S. Genetic polymorphisms and prostate cancer risk. World J Urol 2004;21(6):414-423.
4. Pecina-Slaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 2003;3(1):17.
5. Hazan R, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann NY Acad Sci 2004;1014:155-163.
6. Tsutsumida A, Hamada J, Tada M, Aoyama T, Furuuchi K, Kawai Y, Yamamoto Y, Sugihara T, Moriuchi T. Epigenetic silencing of E- and P-cadherin gene expression in human melanoma cell lines. Int J Oncol 2004;25(5):1415-1421.
7. Lin Y, Wu M, Li D, Wu X, Zheng R. Prognostic and clinicopathological features of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin and cyclin D(1) expression in human esophageal squamous cell carcinoma. World J Gastroenterol 2004;10(22):3235-3239.
8. Salon C, Moro D, Lantuejoul S, Brichon Py P, Drabkin H, Brambilla C, Brambilla E. E-cadherin-beta-catenin adhesion complex in neuroendocrine tumors of the lung: A suggested role upon local invasion and metastasis. Hum Pathol 2004;35(9):1148-1155.
9. Oliveira C, Ferreira P, Nabais S, Campos L, Ferreira A, Cirnes L, Castro-Alves C, Veiga I, Fragoso M, Regateiro F, Moreira Dias L, Moreira H, Suriano G, Machado J, Lopes C, Castedo S, Carneiro F, Seruca R. E-cadherin (CHD1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. Eur J Cancer 2004;40(12):1897-1903.
10. Suriano G, Oliveira M, Huntsman D, Mateus A, Ferreira P, Casares F, Oliveira C, Carneiro F, Machado J, Mareel M, Seruca R. E-cadherin germline missense mutations and cell phenotype: Evidence for the independence of cell invasion on the motile capabilities of the cells. Hum Mol Genet 2003;12(22):3007-3016.
11. Sarrio D, Moreno-Bueno G, Hardisson D, Sanchez-Estevez C, Guo M, Herman J, Gamallo C, Esteller M, Palacios J. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: Relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 2003;106(2):208-215.
12. Wheelock M, Johnson K. Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol 2003;19:207-235.
13. Li L, Zhao H, Nakajima K, Oh B, Alves Ribeiro Filho L, Carroll P, Dahiya R. Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. J Urol 2001;166(2):705-709.
14. Nakamura A, Shimazaki T, Kaneko K, Shibata M, Matsumura T, Nagai M, Makino R, Mitamura K. Characterization of DNA polymorphisms in the E-cadherin gene (CDH1) promoter region. Mutat Res 2002;502(1-2):19-24.
15. Berx G, Becker K, Hofler H, van Roy F. Mutations in the human E-cadherin (CDH1) gene. Hum Mutat 1998;12(4):226-237.
16. Verhage B, van Houwelingen K, Ruijter T, Kiemeney L, Schalken J. Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. Int J Cancer 2002;100(6):683-685.
17. Jonsson B, Adami H, Hagglund M, Bergh A, Goransson I, Stattin P, Wilklund F, Gronberg H. -160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. Int J Cancer 2004;109(3):348-352.
18. Hajdinjak T, Toplak N. E-cadherinpolymorphism-160C/A and prostate cancer. Int J Cancer 2004;109(3):480-481.
19. Kamoto T, Isogawa Y, Shimizu Y, Minamiguchi S, Kinoshita H, Kakehi Y, Mitsumori K, Yamamoto S, Habuchi T, Kato T, Ogawa O. Association of a genetic polymorphism of the E-cadherin gene with prostate cancer in a Japanese population. Jpn J Clin Oncol 2005;35(3):158-161.
20. Tsukino H, Kuroda Y, Imai H, Nakao H, Qiu D, Komiya Y, Inatomi H, Hamasaki T, Kohshi K, Osada Y, Katoh T. Lack of evidence for the association of E-cadherin gene polymorphism with increased risk or progression of prostate cancer. Urol Int 2004;72(3):203-207.
21. Panguluri R, Long L, Chen W, Wang S, Coulibaly A, Ukoli F, Jackson A, Weinrich S, Ahaghotu C, Isaacs W, Kittles R. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 2004;25(6):961-966.
22. Grabe N. AliBaba2: Context specific identification of transcription factor binding sites. In Silico Biol 2002;2(1):S1-S15.
23. Hawley M, Kidd K. Haplo: A program using the EM algorithm to estimate the frequencies of multi-site haplotypes. J Hered 1995;86:409-411.
24. Long J, Williams R, Urbanek M. An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet 1995;56(3):799-810.
25. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12:921-927.
26. Bostwick D. Gleason grading of prostatic needle biopsies: Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 1994;18(8):796-803.
27. Steinberg D, Sauvageot J, Piantadosi S, Epstein J. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997;21(5)566-576.
28. Carlson G, Calvanese C, Kahane H, Epstein J. Accuracy of biopsy Gleason scores from a large uropathology laboratory: Use of a diagnostic protocol to minimize observer variability. Urology 1998;51(4):525-529.
29. Freeman V, Coard K, Wojcik E, Durazo-Arvizu R. Use of the Gleason system in international comparisons of prostatic adenocarcinomas in Blacks. Prostate 200458(2):169-173.
30. Coard K, Freeman V. Gleason grading of prostate cancer. Am J Clin Pathol 2004;122(3):373-376.
31. Pharoah P, Oliveira C, Machado J, Keller G, Vogelsang H, Laux H, Becker K, Hahn H, Paproski S, Brown L, Caldas C, Huntsman D. CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer. Int J Cancer 2002;101(2):196-197.
32. Tsukino H, Kuroda Y, Nakao H, Imai H, Inatomi H, Kohshi K, Osada Y, Katoh T. E-cadherin gene polymorphism and risk of urothelial cancer. Cancer Lett 2003;195(1):53-58.
33. Zhang X, Ma X, Zhu Q, Li L, Chen Z, Ye Z. Association between a C/A single nucleotide polymorphism of the E-cadherin gene promoter and transitional cell carcinoma of the bladder. J Urol 2003;170(4 Pt 1):1379-1382.
34. Humar B, Graziano F, Cascinu S, Catalano V, Ruzzo A, Magnani M, Toro T, Burchill T, Futschik M, Merriman T, Guilford P. Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene 2002;21(53):8192-8195.
35. Rubin M, Mucci N, Figurski J, Fecko A, Pienta K, Day M. E-cadherin expression in prostate cancer: A broad survey using high-density tissue microarray technology. Hum Pathol 2001;32(7):690-697.
36. Kallakury B, Sheehan C, Winn-Deen E, Oliver J, Fisher H, Kaufmann RJ, Ross J. Decreased expression of catenins (alpha and beta), p120CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer 2001;92(11):2786-2795.
37. Wehbi N, Dugger A, Bonner R, Pitha J, Hurst R, Hemstreet Gr. Pan-cadherin as a high level phenotypic biomarker for prostate cancer. J Urol 2002;167(5):2215-2221.
38. Li L, Chui R, Sasaki M, Nakajima K, Perinchery G, Au H, Nojima D, Carroll P, Dahiya R. A single nucleotide polymorphism in the e-cadherin gene promoter alters transcriptional activities. Cancer Res 2000;60:873-876.
39. Avizienyte E, Launonen V, Salovaara R, KiviluotoT, Aaltonen L. E-cadherin is not frequently mutated in hereditary gastric cancer. J Med Genet 2001;38(1):49-52.
40. Haga H, Yamada R, Ohnishi Y, Nakamura Y, Tanaka T. Gene-based SNP discovery as part of the Japanese Millennium Genome Project: Identification of 190,562 genetic variations in the human genome. Single nucleotide polymorphism. J Hum Genet 2002;47(11):605-610.
41. Berx G, Cleton-Jansen A, Nollet F, de Leeuw W, van de Vijver M, Cornelisse C, van Roy F. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995;14(24):6107-6115.
42. Risinger J, Berchuck A, Kohler M, Boyd J. Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet 1994;7(1):98-102.
43. Berx G, Cleton-Jansen A, Strumane K, de Leeuw W, Nollet F, van Roy F, Cornelisse C. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996;13(9):1919-1925.
44. Wu MS, Huang SP, Chang YT, Lin MT, Shun CT, Chang MC, Wang HP, Chen CJ, Lin JT. Association of the -160C→A promoter polymorphism of E-cadherin gene with gastric carcinoma risk. Cancer 2002;94(5):1443-1448.